Brands
Colgate’s latest offering: A toothpaste for diabetics
NEW DELHI: After experimenting with active salt and lemon, Colgate-Palmolive India has come up with a new toothpaste packing the power of Ayurvedic herbs – Colgate for Diabetics, specifically targeting people with diabetes in collaboration with dentists and diabetes experts.
“Colgate for Diabetics aims to bring attention to the bidirectional link between diabetes management and oral health management and provide an effective solution for oral health problems faced by diabetics in an effort to help overall diabetes management,” the company said in a press statement.
The Research Society for the Study of Diabetes in India (RSSDI) and the Indian Society of Periodontology (ISP) came together to study the link between diabetes and oral health. This study has been jointly published by these institutions with clear findings that the right oral care solutions, in addition to lifestyle changes, are crucial in overall diabetes management.
The toothpaste is a clinically proven formula with a blend of ayurvedic ingredients such as madhunashini, neem, jamun seed extract, and amla – a special formula which the company claims kills anaerobic bacteria in the mouth, which is the root cause for many oral health problems for diabetics. This Ayurvedic blend is FDA approved and is available for sale at pharmacies both online and offline.
Colgate-Palmolive India VP – marketing Arvind Chintamani noted that people with diabetes have special oral health needs and there is a two-way connection between oral care and diabetes care.
“India has witnessed a worrying increase in diabetes and unfortunately there is low awareness of the connection between oral health management and diabetes management. Colgate has worked closely with diabetes experts and oral health experts to develop this special daily-use toothpaste simply called Colgate for Diabetics. We are very excited and are looking forward to bringing this terrific innovation to people with diabetes across India,” he added.
The current number of diabetics in India is 77 million, with around 43.9 million estimated left undiagnosed, making the country rank second worldwide, with the largest number of adults and children with diabetes.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
